Clinical Update: News on Two Cancer Gene Editing...
Mar. 24, 2022
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Wugen
Main focus: Off-the-shelf cellular therapies for cancer treatment
Company stage: Clinical
Diseases: T-cell acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), head and neck cancer, melanoma
Genome editing tool: CRISPR-Cas9
Funding stage: Private
Location: San Diego, CA, USA and St. Louis, MO, USA
Website: https://www.wugen.com/
Pipeline: https://www.wugen.com/pipeline/
Wugen is a privately held biotech company. The company focuses on developing CAR-T and natural killer (NK) cells to kill malignant T cells and solid tumours. Wugen uses CRISPR for the deletion of the T-cell receptor (TCR), which enables the use of T cells from healthy donors without the risk of graft-versus-host disease.
Tags
Related News and Updates
Clinical Trials
Relapsed or Refractory T-cell Acute Lymphoblastic Leukaemia, T-ALL (NCT04984356)
Sponsors:
Wugen inc.
Sponsors:
Wugen inc.
IND Enabling
Phase I
Phase II
Phase III
